Nobody reads the cancellation clause on the way in — which is exactly what some subscription architectures count on. We pulled the exit terms across the GLP-1 telehealth market and scored them. The spread is wider than you'd guess: leaving some programs takes one click; others take a support ticket, a notice window, and a retention gauntlet.
Key Takeaways
- The four terms that define an exit: notice window, cancellation channel, commitment-plan exit rules, and refund policy on shipped product.
- Market range: same-day in-account cancellation with no notice window (best) to 7-day notice via support ticket only (worst).
- Commitment plans need a fifth term: the medical-exit policy — what happens if you can't medically continue.
- Rule of thumb: if you can't find the cancellation terms in five minutes before signing up, assume they're bad.
The Scoring Rubric
| Term | Good | Acceptable | Red flag |
|---|---|---|---|
| Notice window | None — effective immediately | 2–3 days before next charge | 5–7+ days |
| Channel | Self-serve button in account | Email with confirmed receipt | Support ticket or phone only |
| Commitment exit | Documented medical-exit policy | Pro-rated buyout | No exit until term ends |
| Refunds | Unshipped orders refundable | Case-by-case, responsive support | All sales final, silence |
What the Market Actually Looks Like
The good end: in-account cancellation, effective immediately, next charge simply doesn't happen, confirmation email arrives unprompted. This exists and is increasingly common — partly because strengthened U.S. click-to-cancel consumer protections have pushed subscription businesses toward symmetric signup/cancel flows.
The middle: a 2–5 day notice window before the billing date, cancellation via a short form or chat, one retention offer on the way out. Livable, if you calendar the window.
The lock-in end: ticket-only cancellation with response lag that conveniently spans the billing date; notice windows that turn a day-of decision into one more full charge; annual commitments with no written medical exit. Any two of those together is a provider telling you who they are.
The Commitment-Plan Question Nobody Asks
Annual pricing at $49–$99/month is genuinely good — but ask, in writing, before committing: "If my clinician discontinues me medically (pregnancy, adverse reaction, non-response), what happens to the remaining term?" The good answer is documented release or pro-rating. A shrug is a no, and a no should change your plan choice even if it doesn't change your provider.
Your Pre-Signup Five Minutes
- Search the help center for "cancel" — note window and channel.
- Find the refund policy for shipped vs. unshipped orders.
- Commitment plan? Get the medical-exit answer in writing.
- Screenshot all of it. Terms pages change; your screenshots don't.
Providers With Clean Exits in Our Tracking
Ivím Health
Compare treatment availability, consultation and membership charges, pharmacy fees and refill policies. Eligibility and medication choice are determined by a clinician.
Pricing, medication access, service area and plan terms must be confirmed with the provider. This is not a drug-specific checkout link.
Explore Ivím Health program ↗Affiliate link: we may earn a commission. This is a different provider from the retired program discussed in older comparisons.
Embody
Injectable semaglutide — $149 first month
Our lead injectable pick: physician-supervised semaglutide with clean flat pricing after the intro month.
Compounded medications are not FDA-approved.
Wellorithm
Oral tablets — sema $147/mo, tirz $249/mo
Lowest published oral compounded pricing on our tracker.
Compounded medications are not FDA-approved.
Verdict: exit terms are the single best proxy for how a provider treats customers it isn't currently acquiring. Read the door before you walk through it.
Affiliate disclosure: Links marked "Paid link" are affiliate links. We may earn a commission if you sign up through them, at no extra cost to you. This supports our independent research.
Compounded medication notice: Compounded medications are not FDA-approved. The FDA does not verify the safety, effectiveness, or quality of compounded drugs before they are marketed. Brand-name alternatives (Wegovy, Ozempic, Zepbound, Rybelsus) are FDA-approved.
Medical disclaimer: This article is for informational purposes only and is not medical advice. GLP-1 medications are prescription drugs. Always consult a licensed healthcare provider about diagnosis, treatment, dosing, and whether these medications are appropriate for you.